Goodbye switch and Imminent Polio Victory

Indian Pediatrics

Volumn 53, Issue 4, 2016, Pages 285-288

  Jog, Pramod ^a  

^a Indian Pediatrics   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; DISEASE SURVEILLANCE; FLACCID PARALYSIS; HEALTH SERVICE; HUMAN; INFECTION CONTROL; NONHUMAN; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; SINGLE DRUG DOSE; VACCINATION; VIRUS TRANSMISSION; WEAKNESS; PREVENTIVE HEALTH SERVICE;

HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL;

EID: 84963722203     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-016-0837-9     Document Type: Article

References (14)

1. Ministry of Health & Family Welfare, Immunization Division. Minutes of the Meeting for tOPV to bOPV Switch. Available from: http://emedinews.in/2016/jan/ Final-Minutes-of-meeting-on-tOPV-to-bOPV-Switch-in-India.pdf. Accessed March 08, 2016.
2. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 — conclusions and recommendations. Wkly Epidemiol Rec. 2014;89:1–20.
3. John TJ, Vashishtha VM. Eradicating poliomyelitis: India’s journey from hyperendemic to polio-free status. Indian J Med Res. 2013;137:881–9
4. World Health Organization. Meeting of the SAGE Polio Working Group.WHO,Geneva,7-8 September 2015. Available from: http://www.who.int/immunization/sage/ meetings/2015/october/2_SAGE_WG_report_draft_Final_clean.ppd. Accessed March 08, 2016.
5. Estivariz CF, Anand A, Gary HE, Rahman M, Islam J, Bari TI, et al. Immunogenicity of three doses of bivalent,trivalent,or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh:an open-label, non-inferiority, randomized, controlled trial. Lancet Infect Dis. 2015;15:898–904.
6. Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet. 1988;1:897–9.
7. Estivariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013;3:309–15.
8. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344–52.
9. Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 1993;341:1545–50.
10. Estivariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: A community-based, randomised controlled trial. Lancet Infect Dis. 2012;12:128–35.
11. John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: An open-label, randomised controlled trial. Lancet. 2014;384:1505–12.
12. Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007;356:1536–44.
13. World Health Organization. Stratagic Advisory Group of Experts on Immunization. Available from: http:// www.who.int/immunization/sage/meetings/2015/october/sage_report_oct_2015.pdf. Accessed March 08, 2016.
14. Patel M, Orenstein W. A world free of polio-The final steps. N Eng J Med. 2016;374:501–3.